1. Validity of Patient-Reported Outcomes Measurement Information System Physical, Mental, and Social Health Measures After Left Ventricular Assist Device Implantation and Implications for Patient Care
- Author
-
Elizabeth A. Hahn, Mary N. Walsh, Larry A. Allen, Christopher S. Lee, Quin E. Denfeld, Jeffrey J. Teuteberg, David G. Beiser, Colleen K. McIlvennan, JoAnn Lindenfeld, Liviu Klein, Eric D. Adler, Josef Stehlik, Bernice Ruo, Katy Bedjeti, Peter D. Cummings, Alyssa M. Vela, and Kathleen L. Grady
- Subjects
Adult ,Male ,Rehabilitation ,heart failure ,Bioengineering ,Middle Aged ,Cardiorespiratory Medicine and Haematology ,Cardiovascular ,Brain Disorders ,female ,Heart Disease ,Mental Health ,Good Health and Well Being ,Cardiovascular System & Hematology ,Clinical Research ,Behavioral and Social Science ,Quality of Life ,Public Health and Health Services ,Humans ,fatigue ,Patient Care ,Heart-Assist Devices ,Patient Reported Outcome Measures ,Cardiology and Cardiovascular Medicine ,Information Systems - Abstract
BACKGROUND: A better understanding is needed of the burdens and benefits of left ventricular assist device (LVAD) implantation on patients’ physical, mental, and social well-being. The purpose of this report was to evaluate the validity of Patient-Reported Outcomes Measurement Information System (PROMIS) measures for LVAD patients and to estimate clinically important score differences likely to have implications for patient treatment or care. METHODS: Adults from 12 sites across all US geographic regions completed PROMIS measures ≥3 months post-LVAD implantation. Other patient-reported outcomes (eg, Kansas City Cardiomyopathy Questionnaire-12 item), clinician ratings, performance tests, and clinical adverse events were used as validity indicators. Criterion and construct validity and clinically important differences were estimated with Pearson correlations, ANOVA methods, and Cohen d effect sizes. RESULTS: Participants’ (n=648) mean age was 58 years, and the majority were men (78%), non-Hispanic White people (68%), with dilated cardiomyopathy (55%), long-term implantation strategy (57%), and New York Heart Association classes I and II (54%). Most correlations between validity indicators and PROMIS measures were medium to large (≥0.3; p CONCLUSIONS: The findings provide convincing evidence for the relevance and validity of PROMIS physical, mental, and social health measures in patients from early-to-late post-LVAD implantation. Findings may inform shared decision-making when patients consider treatment options. Patients with an LVAD, their caregivers, and their clinicians should find it useful to interpret the meaning of their PROMIS scores in relation to the general population, that is, PROMIS may help to monitor a return to normalcy in everyday life. REGISTRATION: URL: https://clinicaltrials.gov ; Unique: identifier: NCT03044535.
- Published
- 2023